Eckert & Ziegler to Open up US-Production Site for Yttrium-90

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG

/ Key word(s): Expansion

05.02.2020 / 14:35

The issuer is solely responsible for the content of this announcement.

Berlin, February 5, 2020. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) will open up a radiopharmaceutical production site in the Boston area and has signed a long-term rental contract for a suitable building in Wilmington, Massachusetts. Mirroring the technology of Eckert & Ziegler’s European plant, it is planned as first step to produce Yttrium-90, a short-lived radioisotope which is e.g. used in oncological applications for the treatment of liver cancer.

The decision to open a sister plant in the United States was facilitated by a competitor’s decision to close their existing older production line for Y-90 in June later this year. It had already been considered as the next step in Eckert & Ziegler’s global expansion strategy. Previously in 2019 Eckert & Ziegler had agreed to bring its Y-90 production technology to a partner in Chengdu, China, in return giving Eckert & Ziegler long-term, exclusive global marketing and sales rights. Once the Boston plant is operational, Eckert & Ziegler will be able to offer local supply of Y-90 to pharmaceutical companies or hospitals in all regions of the world.

“The geo strategy of Eckert & Ziegler, which offers a reliable, redundant and local supply of high-quality radioisotopes, has hit a nerve in the industry”, explained Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG. “Our American customers have already committed to procure a substantial part of their demand from the new Boston site, scheduled for full operational readiness in 2021. For the transition period, while the plant is being built, our existing European facility is able to cover any shortfalls”.

About Eckert & Ziegler.
Eckert & Ziegler is one of the leading suppliers of Yttrium-90 for oncological applications. The radioisotope is often being used as precursor in medical devices for treatment of hepatocellular carcinomas. The process, which is also known as radioembolization, has found increased acceptance worldwide. With more than 800 employees, Eckert & Ziegler is one of the world’s largest providers of isotope-related components for radiation therapy and nuclear medicine. The group’s shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de


05.02.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 968921

 
End of News DGAP News Service

show this